Skip to content

Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00791323
Enrollment
9
Registered
2008-11-14
Start date
2008-11-30
Completion date
2009-08-31
Last updated
2011-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation

Brief summary

A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy

Interventions

One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days

DRUGLubricating Eye Drop

One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation

Sponsors

Allergan
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients scheduled to undergo phakic IOL implantation

Exclusion criteria

* History of intraocular surgery in the operative eye

Design outcomes

Primary

MeasureTime frameDescription
Mean Prostaglandin E2 (PGE2) Aqueous Humor LevelsDay 3The mean level of PGE2 (a naturally occurring prostaglandin E2 in the eye that can cause inflammation and other complications) in the aqueous humor (the thin, watery fluid in the eye) 2 days following peripheral iridotomy (ocular surgery).

Countries

United States

Participant flow

Participants by arm

ArmCount
Ketorolac 0.4%
Ketorolac 0.4%
6
Soothe® XP
Mineral Oil Emollient
3
Total9

Baseline characteristics

CharacteristicKetorolac 0.4%Soothe® XPTotal
Age Continuous30.2 years
STANDARD_DEVIATION 9.7
33.3 years
STANDARD_DEVIATION 2.5
31.75 years
STANDARD_DEVIATION 6.1
Sex: Female, Male
Female
5 Participants1 Participants6 Participants
Sex: Female, Male
Male
1 Participants2 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 60 / 3
serious
Total, serious adverse events
0 / 60 / 3

Outcome results

Primary

Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels

The mean level of PGE2 (a naturally occurring prostaglandin E2 in the eye that can cause inflammation and other complications) in the aqueous humor (the thin, watery fluid in the eye) 2 days following peripheral iridotomy (ocular surgery).

Time frame: Day 3

Population: Intent to Treat defined as all patients who started the study (randomized) with processed aqueous samples. Two patients in the Ketorolac 0.4% arm did not have aqueous humor samples processed.

ArmMeasureValue (MEAN)Dispersion
Ketorolac 0.4%Mean Prostaglandin E2 (PGE2) Aqueous Humor Levels1027.4 Picograms per milliliter (pg/ml)Standard Deviation 429
Soothe® XPMean Prostaglandin E2 (PGE2) Aqueous Humor Levels1014.7 Picograms per milliliter (pg/ml)Standard Deviation 196.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026